Please try another search
AXIM Biotechnologies, Inc. engages in the development and sale of diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and other diseases. The company is developing tests for dye eye diseases; SARS-CoV-2 neutralizing antibody tests; and fentanyl neutralizing antibody tests. It also developing a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Timothy Richard Scott | 71 | 2017 | Independent Director |
Robert L. Cunningham | 76 | 2017 | Independent Director |
Michael E. Stern | - | 2021 | Member of Medical Advisory Board |
Blake N. Schroeder | 47 | 2022 | Director |
John W. Huemoeller | 69 | 2017 | President, CEO & Director |
Peter M. O’Rourke | 51 | 2020 | Director |
Laura M. Periman | - | 2021 | Member of Medical Advisory Board |
Henry D. Perry | 97 | 2021 | Member of Medical Advisory Board |
Kelly K. Nichols | - | 2021 | Member of Medical Advisory Board |
Joseph Tauber | 67 | 2021 | Chief Medical Officer & Chairman of the Medical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review